Long-term Alendronate Therapy and Subtrochanteric Femoral Fractures

REFERENCES

1. ↵
   1. Odvina C. V.,
   2. Zerwekh Z. E.,
   3. Rao D. S.,
   4. Maalouf N.,
   5. Gottschalk F. A.,
   6. Pak C. Y.

   (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90((3)):1294–1301, pmid:15598694.

   OpenUrlCrossRefPubMedWeb of Science
2. ↵
   1. Frost H. M.

   (1960) Presence of microscopic cracks in vivo in bone. Henry Ford Hosp Med Bull 8:27–35.

   OpenUrl
3. ↵
   1. Schneider J. P.

   (2009) Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk. Geriatrics 64((1)):18–23, pmid:19256578.

   OpenUrlPubMedWeb of Science